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Background: Recent studies have shown that miR-199a-5p plays opposite roles in cancer initiation and progression
of different cancer types, acting as oncogene for some cancer types but as tumor suppressor gene for others.
However, the role and molecular mechanism of miR-199a-5p in gastric cancer are largely unknown.
Methods: In this study, miR-199a-5p expression level in gastric cancer was first analyzed by qPCRand then validated
in 103 gastric cancer patients by in situ hybridization (ISH). Gastric cancer cell lines were transfected with
miR-199a-5p inhibitor and mimic, and underwent in vitro transwell assays. Target genes (klotho) were identified
using Luciferase reporter assay. Immunohistochemical staining was also used to investigate on how miR-199a-5p
regulates the tumour-suppressive effects of klotho in gastric cancer.
Results: In our present study, we found that miR-199a-5p level was significantly increased in gastric cancer tissues
compared to paired normal tissues. We observed that miR-199a-5p could promote migration and invasion of gastric
cancer cells. In situ hybridization of miR-199a-5p also confirmed that higher miR-199a-5p expression level was
associated with increased likelihood of lymph node metastasis and later TNM stage. Luciferase reporter assay and
immunohistochemistry revealed that klotho might be the downstream target of miR-199a-5p.
Conclusions: Our present study suggests that miR-199a-5p acts as an oncogene in gastric cancer and functions by
targeting klotho.
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Gastric cancer (GC) is the fourth most common cancer in
human and the second most common cause of cancer-
related death in the world [1]. GC appears to be caused by
various endogenous and exogenous factors. In recent
years, microRNAs (miRNAs), a class of endogenous small
noncoding regulatory RNAs with approximately 22 nucle-
otides in length, are believed to contribute to cancer initi-
ation and progression by regulating gene expression, and
act as oncogenes or tumor suppressor genes depending
on the targets they regulate [2]. miRNAs have been
identified as a new type of gene regulators that bind to* Correspondence: hzm6606@hzcnc.com; taohouquan2008@aliyun.com
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unless otherwise stated.the 3'-untranslated regions (UTRs) of target mRNA,
thereby regulating gene expression by repressing trans-
lation or decreasing the stability of mRNA [3]. More re-
cent studies have demonstrated that miRNA alterations
are associated with pathogenesis and progression of
cancer [3,4], because miRNAs are mainly located in
cancer-associated genomic regions, such as fragile sites,
minimal regions of loss of heterozygosity and minimal
regions of amplification [3].
In 2003, the identity of miR-199a was computationally
predicted based on its conservation between human,
mouse and pufferfish [5]. Expression of the miRNA was
validated in zebrafish, and its ends were mapped by
cloning. The two miRNA sequences were named miR-
199a and miR-199a* (from the 3’ arm), respectively. The
mature forms of both miRNAs were reported to be
expressed in humans, and were named miR-199a-5p and
miR-199a-3p, respectively [6]. Recent studies showedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of different cancer types, acting as oncogene for some
cancer types but as tumor suppressor gene for others.
miR-199a is downregulated in ovarian cancer tissues and
cell lines, and overexpression of miR-199a inhibits
tumor-induced angiogenesis [7]. Another study also
found that expression of endogenous mature miR-199a
might prevent tumorigenesis in human ovarian cancer
[8]. Other reports showed that miR-199a suppressed cell
growth in renal cancer [9] and inhibited cell prolifera-
tion in human Hepatocellular carcinoma (HCC) [10].
Huang et al. also found that miR-199a-5p was signifi-
cantly down-regulated in advanced stage in small cell
carcinoma of the cervix (SCCC) patients, and was asso-
ciated with lymph node metastasis, reducing survival in
SCCC [11]. On the other hand, Song et al. [12] found
that miR-199a was highly expressed in gastric cancer
tissues compared to normal gastric tissues, and in meta-
static gastric cancer tissues compared to non-metastatic
ones. Zhang et al. also found that miR-199a was an
oncogene in human gastric tumourigenesis [13]. How-
ever, the molecular mechanisms underlying this process
have not been documented.
Klotho gene is located on chromosome 13q12 [14],
which encodes a 130-kDa transmembrane protein that is
predominantly expressed in the distal tubule of the
kidney, and less frequently in several other tissues [15].
Analysis of klotho cDNA revealed two alternatively
spliced transcripts, which encode two distinct proteins,
namely, membrane klotho and secreted klotho. Studies
have shown that secreted klotho can suppress autophos-
phorylation of insulin-like growth factor (IGF) type I re-
ceptor (IGF-IR) [16]. As IGFs are associated with cancer
risk and tumor progression [17], it is speculated that
klotho may be involved in tumorigenesis as an anti-
tumor molecule. A study by Usuda et al. suggested that
klotho provides a new biomarker for good outcome in
patients with large cell neuroendocrine carcinoma of the
lung, especially among patients without lymph node me-
tastasis or lymphangio invasion [18]. Klotho suppresses
epithelial-mesenchymal transition, and inhibits tumor
migration and invasion during renal cell carcinoma pro-
gression, thus acting as a tumor suppressor [19]. How-
ever, some laboratory experiments showed that klotho
was able to stimulate angiogenesis and inhibit apoptosis
[20,21]. Thus, it is important to explore the expression
of klotho in different types of cancer and its association
with tumor progression. Recent studies found that
klotho was an epigenetically inactivated tumor suppres-
sor in gastric cancer, and regulated tumor cell prolifera-
tion, apoptosis, and autophagy [22,23]. However, the
regulatory mechanism of klotho in gastric cancer re-
mains unclear. In the present study, we analyzed miR-
199a-5p expression in gastric cancer, and investigated itseffects on the modulation of klotho and its contribution
to human gastric cancer.
Methods
Cell culture
Human gastric cancer cell lines MKN-45, MKN-28, SGC-
7901, BGC-823, HGC-27, AGS and human gastric muco-
sal epithelial cell line GES-1 were purchased from Cell
Bank of Shanghai Institute of Cell Biology (Shanghai,
China). All cell lines were passaged for fewer than
3 months after resuscitation. They were all cultured in
RPMI1640 (HyClone, Logan, UT, USA) containing 10%
fetal bovine serum (FBS) and antibiotics (100 U/mL
streptomycin and 100 U/mL penicillin), and maintained at
37°C in 5% CO2. Cells were passaged at 80% confluency
using 1 mmol/L EDTA–0.025% trypsin for 3–5 min.
Clinical samples
Thirty four fresh specimens from patients with GC (25
male and 9 female patients aged 28–73 years) were
acquired from Zhejiang Provincial People’s Hospital
between January 2010 and December 2010, and stored
at −80°C. Surrounding normal gastric mucosas were also
obtained for this study. One hundred and three paraffin-
embedded specimens of GC patients (75 male and 28
female patients aged 31–78 years, collected from January
1998 to December 2004) were acquired from Zhejiang
Provincial People’s Hospital. All patients had not re-
ceived radiotherapy or chemotherapy prior to surgery,
and had follow-up data over 5 years until December
2009. Tumor grade was determined according to various
classifications of Tumors. Forty two cases were of intes-
tinal type and 61 cases were of diffuse type according to
Lauren classification. 3 cases were well differentiation,
27 moderately differentiated and 73 poorly differentiated
by pathological grading. 1 case was papillary adenocar-
cinoma, 83 tubular adenocarcinoma, 9 mucinous adeno-
carcinoma and 10 signet-ring cell carcinoma, according
to the WHO histological classification. 60 cases showed
lymph node metastasis and 43 did not. 6 cases showed
distant metastasis and 97 did not. 24 cases were in TNM
stage I, 30 in TNM stage II, 39 in TNM stage III and 10
in TNM stage IV. Written informed consent was ob-
tained from all patients before analysis. The project was
approved by the ethics committee of Zhejiang Provincial
People’s Hospital.
RNA extraction, cDNA preparation and quantitative qPCR
Total RNA was extracted from cell lines and fresh speci-
mens using Trizol (Invitrogen, USA) according to the
manufacturer’s handbook. cDNA was prepared using
Superscript III cDNA synthesis kit (Invitrogen, USA)
following the manufacturer’s protocol. qPCR was carried
out using SYBR Premix Ex Taq (Takara, Japan) with
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dogenous control. The specific forward primer for RNU6B
was 5′-ACGCAAATTCGTGAAGCGTT-3′. The specific
primer for miR-199a-5p was 5′-CCCAGTGTTCAGAC-
TACCTGTTC-3′. PCR parameters were as follows: 95°C
for 5 min, followed by 40 cycles of 95°C for 10 s, 58°C for
20 s and 72°C for 20 s. At the end of the PCR cycles, melt-
ing curve analysis was performed. MiR-199a-5p expres-
sion level in the tumor tissues was directly compared to
that in the matched normal tissues, and relative expres-
sion level was calculated using the 2−ΔΔCT method. The
expression level of miR-199a-5p in gastric cancer cell lines
was calculated using the 2−ΔCT method and compared to
that in GES-1.
miR-199a-5p transfection
GC cells were grown in six-well dishes (plated at 5.0 × 105
cells per well) for 24 h before transfection. miR-199a-5p
inhibitor (Anti-hsa-miR-199a-5p miScript miRNA Inhibi-
tor, MIN0000231, Qigen, USA) was transfected into
MKN-28 and MKN-45, which had a relatively high
expression level of miR-199a-5p compared with normal
gastric cell line GES-1 and other gastric cancer cells. miR-
199-5p mimic (Syn-hsa-miR-199a-5p miScript miRNA
Mimic, MSY0000231, Qigen, USA) was transfected into
AGS and BGC-823, which had a relatively low expression
level of miR-199a-5p compared with normal gastric cell
line GES-1 and other gastric cancer cells. Inhibitor nega-
tive control (miScript Inhibitor Neg. Control, 1027271,
Qigen, USA) and mimic negative control groups were also
set up. Transfection was performed with Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
protocol.
Transwell assay
Twenty four hours after transfection, GC cells were used
for migration and invasion assays. Transwell migration
assay was carried out in 24-well plates using costar
transwell assay kit (3422, Corning, USA). The invasion
assay was carried out using invasion chambers (354480;
BD, USA) pre-coated with Matrigel. Cells (2.0 × 105 per
well) were seeded in the upper chamber, and NIH 3 T3
fibroblast conditioned medium was added to the lower
chamber. After 48 h of incubation at 37°C in 5% CO2,
unmigrated cells or noninvasive cells were removed
from the upper surface of the transwell membrane with
a cotton swab, and the migrated or invaded cells on the
lower membrane surface were fixed, stained, photo-
graphed, and counted under high-power magnification
(×200).
Luciferase reporter assay and Target gene indentify
The pYr-MirTarget-Klotho-3′-untranslated region (UTR)
luciferase vector containing the putative binding site ofmiR-199a-5p was purchased from Yinrun Biotechnology
(Changsha, China). HEK293 cells were plated in 96-well
plates. Then the cells were co-transfected with the pYr-
MirTarget-Klotho-3′UTR reporter plasmids using Lipo-
fectamine 2000 reagent (Invitrogen) and hsa-miR-199a-5p
mimics (100nM). After 48 h, luciferase activities were
measured using the Dual-Luciferase Reporter Assay reagent
(Promega) on Sirius single tube luminometer (Berthold
Technologies, GmbH & Co. KG, Bad Wildbad, Germany).
The pYr-MirTarget-Klotho-3UTR-D reporter vector
was constructed by site-directed mutagenesis of hsa-
miR-199a-5p at its putative binding site of klotho 3′
UTR. Then three groups of HEK293 cells were taken,
and the first group was co-transfected with the
pYr-MirTarget-Klotho-3UTR reporter plasmids and
hsa-miR-199a-5p mimics (50nM), the second group co-
transfected with the pYr-MirTarget-Klotho-3UTR-D
reporter plasmids and hsa-miR-199a-5p mimics (50nM),
and the third group co-transfected with pYr-MirTarget
report plasmid and hsa-miR-199a-5p mimics as negative
control. After 48 h, luciferase activities were measured
using the Dual-Luciferase Reporter Assay reagent. Firefly
luciferase activity was normalized to renilla luciferase
activity for each transfected well. All transfection experi-
ments were conducted in triplicate and repeated 3 times
independently.
To further confirm the klotho as a target genes of
miR-199a-5p in gastric cancer cells. After transfected
with miR-199a-5p inhibitor or mimic in gastric cancer
cells the transfection efficiency and expression levels of
klotho at both the mRNA and protein levels were tested
by using qPCR and Western-bloting method.
In situ hybridization
In situ hybridization was performed on 5 μm paraffin
sections to investigate the clinical and biological relevance
of miR-199a-5p in GC development using sensitivity-
enhanced in situ hybridization kits (MK1030, Boster
Biological Technology, Wuhan, China). Digoxin-labelled
miR-199a-5p probe (miRCURY LNA™ Detection probe,
250 pmol, 5`-DIG labeled, Exiqon, Denmark) was used to
detect cytoplasmic miR-199a-5p staining. Staining pat-
terns were examined by two reviewers independently.
Immunohistochemical staining
Each tissue section was deparaffinized, rehydrated and
then rinsed with PBS. High pressure antigen retrieval
was carried out in 0.01 M citrate buffer (pH 6.0). The
sections were incubated with 3% H2O2 for 10 min
followed by 10% normal goat serum for 15 min at room
temperature. Then the sections were incubated with
rabbit anti-human klotho polyclonal antibody (1:250 di-
lutions in PBS, ab69208, Abcam, HK) overnight at 4°C,
rinsed with PBS, incubated with biotin labeled secondary
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with PBS, and incubated with horseradish peroxidase
polymer conjugate (Zymed) for another 20 min at room
temperature. Subsequently, they were stained with 3,3-
diaminobenzidine and counterstained with hematoxylin.Evaluation of in situ hybridization and
immunohistochemical staining
The staining intensity of each tissue section was assessed
by the average signal intensity and the percentage of
positive cells. The average signal intensity was graded on a
scale of 0 to 3+ (0 for no staining, 1+ for weak staining,
2+ for moderate staining, and 3+ for strong staining).Figure 1 The expression level of miR-199a-5p in GC tissues and gastr
miR-199a-5p was higher in 34 GC tissues than in their pair-matched adjace
normalized to RNU6B. (B) The relative miR-199a-5p expression in gastric ca
expression of miR-199a-5p was normalized to the endogenous control RNUThe percentage of cells that showed positive staining
within the tissue sections was scored as follows: 1 for
0%–25% of cells positive, 2 for 26%–50% positive, 3 for
51%–75% positive and 4 for 76%–100% positive. The
staining intensity score and the percent immunoreactiv-
ity score were then multiplied to obtain a composite
score. The values of the composite score ranged from a
minimum of 0 to a maximum of 12, and a score of 0 to
3 was defined as negative, while a score of ≥4 was
defined as positive.
Statistical analysis
Statistical analysis were performed using SPSS software
version 13.0 (SPSS Inc., Chicago, IL, USA), and all Pic cancer cell lines examined by qPCR. (A) Expression level of
nt normal tissues (P < 0.05). Each sample was analyzed in triplicate and
ncer cell lines was much higher than that of GES-1. The relative
6B. Each sample was analyzed in triplicate.
Figure 2 Transwell assay of miR-199a-5p. (A) Gastric cancer cells MKN-45 and MKN-28 were transfected with miR-199a-5p inhibitor and
showed reduced migration activity compared with the negative control. BGC-823 and AGS were transfected with miR-199a-5p mimic and showed
increased migration activity compared with the negative control. (B) Gastric cancer cells MKN-45 and MKN-28 were transfected with miR-199a-5p
inhibitor and showed reduced invasion activity compared with the negative control. BGC-823 and AGS were transfected with miR-199a-5p mimic
and showed increased invasion activity compared with the negative control.
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considered statistically significant. miR-199a-5p mRNA
level obtained by qPCR and relative Luciferase activities
were expressed as mean ± standard deviation. If the results
were normally distributed, their means were compared by
either paired sample t-test or one-way ANOVA, as appro-
priate. If the results were not normally distributed, theFigure 3 In situ hybridization analysis of miR-199a-5p expression in g
gastric cancer tissue, A: magnification × 100, C: magnification × 400; (B, D)
magnification × 100, D: magnification × 400.Wilcoxon test or Kruskal-Wallis H test was used to com-
pare multiple related groups of samples, as appropriate.
miR-199a-5p level obtained by In Situ Hybridization and
klotho expression level obtained by Immunohistochemical
Staining (categorical data) were described by their fre-
quency and analyzed by Chi-square test (or Fisher’s exact
test) and nonparametric test. Spearman’s rank correlationastric cancer tissue. (A, C) negative expression of miR-199a-5p in
positive expression of miR-199a-5p in gastric cancer tissue, B:
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miR-199a-5p and klotho expression levels.
Results
MiR-199a-5p is up-regulated in gastric cancer tissues and
cell lines
The expression level of miR-199a-5p in a total of 34
matched gastric cancer tissues and adjacent normal
tissues was analyzed using qPCR. MiR-199a-5p level was
found to be higher in gastric cancer tissues compared to
paired normal tissues (Figure 1A). miR-199-5p expres-
sion level in gastric cancer cell lines MKN-45, MKN-28,
SGC-7901, BGC-823, HGC-27, and AGS was compared
with miR-199-5p expression level in human gastric
normal epithelial mucosa cell line GES-1. As shown in




Male 75 47 (62.7%
Female 28 18 (64.3%
Tumor diameter
<5 cm 74 41 (55.4%
≥5 cm 29 24 (82.8%
Lauren classification
Diffuse type 42 31 (73.8%
Intestinal type 61 34 (55.7%
Differentiation
Well 3 2 (66.7%)
Moderate 27 17 (63.0%
Poor or no 73 46 (63.0%
Histology type
Papillary adenocarcinoma 1 1 (100.0%
Tubular adenocarcinoma 83 51 (61.4%
Mucinous adenocarcinoma 9 6 (66.7%)
Signet-ring cell carcinoma 10 7 (70.0%)
Lymph node metastasis
Yes 60 46 (76.7%
No 43 19 (44.2%
Distant metastasis
Yes 6 6 (100.0%
No 97 59 (60.8%
TNM stage
I 24 9 (37.5%)
II 30 16 (53.3%
III 39 31 (79.5%
IV 10 9 (90.0%)miR-199a-5p than GES-1. Among the gastric cancer cells,
MKN-28 and MKN-45 have a relatively high expression of
miR-199a-5p and AGS、BGC-823 have a relatively low
expression of miR-199a-5p.The role of miR-199a-5p in migration and invasion of
gastric cancer
In order to explore the function of miR-199a-5p in
gastric cancer, miR-199a-5p expression level was ec-
topically raised in gastric cancer cells BGC-823 and
AGS using miR-199a-5p mimic, and was reduced in
MKN-45 and MKN-28 with miR-199a-5p inhibitor.
Then the effects of miR-199a-5p on the migratory and
invasive behavior of gastric cancer cell lines were
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gastric cancer cells MKN-45 and MKN-28 that were
transfected with miR-199a-5p inhibitor showed decreased
number of migrated cells compared with negative control
(P < 0.05). Meanwhile, the migration activity of gastric
cancer cells BGC-823 and AGS that were transfected with
miR-199a-5p mimic was significantly increased compared
with negative control (P < 0.05).
From the in vitro invasion assay (Figure 2B), invasion
ability of gastric cancer cells MKN-45 and MKN-28 was
substantially reduced by miR-199a-5p inhibitor com-
pared with negative control (P < 0.05). On the other
hand, miR-199a-5p mimic enhanced invasion ability of
gastric cancer cells BGC-823 and AGS (P < 0.05).
Clinical significance of miR-199a-5p in gastric cancer
In situ hybridization showed that miR-199a-5p was mainly
localized in the cytoplasm of gastric cancer cells (Figure 3).
Among 103 cases, miR-199a-5p expression was detected
in 63.1% (65/103) of the GC specimens, and expression
level of miR-99a-5p was found to be associated with
tumor diameter, lymph node metastasis and TNM stage
(Table 1), but unrelated to gender, Lauren classification
type, tumor differentiation, histological type and distantFigure 4 klotho is a direct target of miR-199a-5p. (A) Profile of pYr-Mir
two miR-199a-5p target sites in klotho 3′UTR, showing sequence alignmen
dramatically decreased in the presence of miR-199a-5p mimic when comp
sample was normalized by Firefly luciferase activity. Data were shown as m
HEK293 cells were co-transfected with luciferase reporter plasmid containin
klotho-Mut), and the luciferase activity of wild type klotho became much lo
miR-199a-5p was introduced (*P < 0.05).metastasis (P > 0.05) (Table 1). The percentage of tissues
from patients with tumor diameter ≥5 cm that showed
positive staining of miR-199a-5p was 82.8% (24/29), which
was higher than from patients with tumor diameter <5 cm
(55.4%, 41/74, χ2 = 6.696, P = 0.010). The percentage of
tissues from patients with lymph node metastasis that
showed positive staining of miR-199a-5p was 76.7%
(46/60), which was higher than from patients without
lymph node metastasis (44.2%, 19/43, χ2 = 11.350, P= 0.001).
The detection rate of miR-199a-5p was 37.5% (9/24) in
TNM stage I, 53.3% (16/30) in TNM stageII, 79.5% (31/39)
in TNM stage III, 90.0% (9/10) in TNM stage IV, which
revealed significant differences (χ2 = 15.591, P= 0.001).Klotho is the target gene of miR-199a-5p
Candidate target genes of miR-199a-5p were computa-
tionally screened by using miRBase Targets, TargetScan
Release 5.0 and PicTar databases, and klotho was found
to be a downstream target of miR-199a-5p. The pYr-
MirTarget-Klotho-3′- UTR luciferase vector (Figure 4A)
was used to detect the target gene of miR-199a-5p.
Further investigation showed that the 3′UTR of klotho
mRNA had 2 sites targeted by miR-199a-5p (Figure 4B).Target-Klotho-3′UTR luciferase report plasmid; (B) The positions of the
t of miR-199a-5p and the klotho 3′UTR; (C) Luciferase activity was
ared with negative control (*P < 0.05). Renilla luciferase activity of each
ean ± standard deviation from three independent experiments. (D)
g either wild type or mutant klotho 3′UTR (indicated as klotho-Wt or
wer than that of mutant type klotho and negative control when
Figure 5 The transfection efficiency of miR-199a-5p and klotho target gene indentify in gastric cancer cells. (A, B) The transfection
efficiency of miR-199a-5p inhibitor (MKN-45, MKN-28) and mimic (BGC-823, AGS) in gastric cancer cell. (C, D) The mRNA level changes of klotho
after gastric cancer cell transfected with miR-199a-5p inhibitor (MKN-45, MKN-28) and mimic (BGC-823, AGS). (E, F) The protein expression
changes of klotho in gastric cancer cells after transfected with miR-199a-5p inhibitor (MKN-45, MKN-28) and mimic (BGC-823, AGS).
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3′-UTR region of klotho, we fused part of the human
klotho 3′UTR with pYr-MirTarget-Klotho-3UTR re-
porter and transfected it into HEK293 cells, with one
group in the presence of miR-199a-5p mimics and the
other in the presence of miRNA negative control. Lucif-
erase activity was lower in the presence of miR-199a-5p
when compared with negative control (P < 0.05, Figure 4C).
Then another reporter construct was cloned in which
the conserved targeting region of miR-199a-5p was spe-
cifically mutated. We subsequently co-transfected miR-
199a-5p mimics with two groups of luciferase reporterFigure 6 Immunohistochemical staining for klotho in gastric cancer t
gastric cancer tissue, A:magnification × 100, C: magnification × 400; (B, D) po
D: magnification × 400.constructs, with one containing wild type (klotho-wt)
klotho 3′-UTR, and the other containing mutant
(klotho-mut) klotho 3′-UTR. miR-199a-5p was found to
significantly reduce wild type klotho luciferase activity
by approximately 23% when compared with negative
control (P < 0.05, Figure 4D), but it did not alter activity
of the mutant klotho luciferase reporter, indicating that
miR-199a-5p specifically acts on wild-type klotho 3′-
UTR.
In gastric cancer cells of MKN-28 and MKN-45,
down-regulated the expression level of miR-199a-5p by
using miR-199a-5p inhibitor, the both mRNA andissues, ×400 magnification. (A, C) negative expression of klotho in
sitive expression of klotho in gastric cancer tissue, B: magnification × 100,
Table 2 Correlation between klotho expression and clinicopathological features of gastric cancer





Male 75 44 (58.7%) 31
Female 28 17 (60.7%) 11
Tumor diameter 3.464 0.063
<5 cm 74 48 (64.9%) 26
≥5 cm 29 13 (44.8%) 16
Lauren classification 1.375 0.241
Diffuse type 61 39 (63.9%) 22
Intestinal type 42 22 (52.4%) 20
Differentiation 0.203 1.000
Well 3 2 (66.7%) 1
Moderate 27 16 (59.3%) 11
Poor or no 73 43 (58.9%) 30
Histology classification 3.220 0.347
Papillary adenocarcinoma 1 0 (0.0%) 6
Tubular adenocarcinoma 83 48 (57.8%) 48
Mucinous adenocarcinoma 9 5 (55.6%) 32
Signet-ring cell carcinoma 10 8 (80.0%) 4
Lymph node metastasis 7.058 0.008
Yes 60 29 (48.3%) 31
No 43 32 (74.4%) 11
Distant metastasis 4.778 0.040
Yes 6 1 (16.7%) 5
No 97 60 (61.9%) 37
TNM stage 16.763 0.001
I 24 22 (91.7%) 2
II 30 18 (60.0%) 12
III 39 18 (46.2%) 21
IV 10 3 (30.0%) 7
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BGC-823 and AGS, which transfected with miR-199a-5p
mimic, the klotho expression levels were reduced
(Figure 5). These results indicate that klotho is a target
gene of miR-199a-5p.Table 3 Correlationship between miR-199a-5p and klotho





Klotho expression −0.379 0.00007
Negative 10 32
Positive 38 23Correlation between miR-199a-5p and klotho expression
level in gastric cancer
The 103 GC samples were also examined for klotho
expression level. Yellowish-brown klotho granules were
observed mainly in the cytoplasms (Figure 6). The per-
centage of klotho-positive specimens was 59.2% (61/103),
and klotho detection rate was found to be statistically
correlated with lymph node metastasis, distant metasta-
sis and TNM stage. Among patients with lymph node
metastasis, 48.3% (29/60) were klotho positive, which
was lower than those without lymph node metastasis
(74.4%, χ2 = 7.058, P = 0.008). Among patients with dis-
tant metastasis, 16.7% (1/6) were klotho positive, which
was lower than those without distant metastasis (61.9%,
60/97, χ2 = 4.778, P = 0.040). The detection rate of
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in TNM stageII, 46.2% (18/39) in TNM stage III, 30.0%
(3/10) in TNM stage IV, which showed significant
differences (χ2 = 16.763, P = 0.001). However, klotho
detection rate was not associated with gender, tumor
diameter, Lauren classification type, differentiation and
histological type (P > 0.05) (Table 2).
We also found a negative correlation between expres-
sion level of miR-199a-5p and klotho in gastric cancer
(R = −0.379, P = 0.00007, Spearmen’s ρ-test, Table 3).
Discussion
While recent studies showed that miR-199a alterations
were associated with pathogenesis and progression of
cancer, they have proposed conflicting roles for miR-
199a in carcinogenesis and tumour progression. Some
studies reported that miR-199a may play as tumor
suppressor in ovarian cancer and renal cancer [8,9], and
another study reported that miR-199a may play an
oncogenic role in SCCC [11]. However, little is known
about the functional role of miR-199a-5P in gastric can-
cer. In our present study, we found that miR-199-5p
level was significantly increased in gastric cancer tissues
compared to paired normal tissues, which suggests that
miR-199-5p may play an oncogenic role in human gas-
tric cancer. This result is consistent with the report of
Song et al. [12]. Furthermore, we also analyzed the
biological role of miR-199-5p on gastric cancer cell lines.
Using transwell migration and invasion assay, we
observed that miR-199a-5p promotes migration and
invasion of gastric cancer cells. In situ hybridization of
miR-199a-5p also confirmed that higher miR-199a-5p
expression level is associated with increased likelihood
of lymph node metastasis and later TNM stage. These
results further revealed that miR-199a-5p may be in-
volved in carcinogenesis and development of gastric can-
cer, and act as an oncogene in gastric cancer. However,
Shen et al. reported that increased expression of miR-
199a-5p contributes to decreased cell invasion in HCC
[24]. These conflicting results may be due to different
tumor characteristics between GC and HCC, and needs
to be confirmed by further studies.
To understand the functional mechanism of miRNAs,
identifying their regulatory targets is crucially important.
In our study, by scanning through internet databases
miRBase Targets, TargetScan Release 5.0 and PicTar, we
identified klotho as a downstream target of miR-199a-
5p. Recent studies showed that klotho acted as an inhibi-
tor of IGF-1 pathways [15,16,25], indicating that klotho
might be involved in cancer development by remodeling
the interaction of tumor-initiating cells with their micro-
environment. Wang et al. found that klotho was a novel
tumor suppressor gene which is silenced through pro-
moter hypermethylation in gastric cancer [22]. In ourpresent study, we also found that klotho expression level
was negatively associated with lymph node metastasis,
distant metastasis and TNM stage. The results show that
klotho may act as a tumor suppressor in gastric cancer,
and further investigations can be performed on how
miR-199a-5p regulates the tumor-suppressive effects of
klotho in gastric cancer. Other studies found klotho to
be a tumor suppressor in lung, renal, ovarian, pancreatic
and cervical cancer [8-10,26-28]. However, Lu et al.
reported that high level of expression of secreted klotho
was associated with increased risk of disease progression
and death in epithelial ovarian cancer [29]. Therefore,
the function of klotho in different tumor types may be
further investigated to explain the conflicting results.
To confirm whether miR-199a-5p directly interacts
with 3′-UTR region of the target genes (klotho), we
fused part of human klotho 3′UTR with pYr-MirTarget-
Klotho-3U reporter and transfected it into HEK293 cells
in the presence of either miR-199a-5p mimics or miRNA
negative control. We found that luciferase activity was
significantly decreased in the presence of miR-199a-5p
when compared with miRNA negative control. Addition-
ally, miR-199a-5p did not alter activity of the mutant
klotho luciferase reporter, and specifically acted on wild-
type klotho 3′-UTR. Immunohistochemistry analysis re-
vealed that there is a negative correlation between the
expression level of miR-199a-5p and klotho in gastric
cancer, indicating that klotho may be downstream target
of miR-199a-5p.
Conclusion
In conclusion, this study provides new insights into the
role of miR-199a-5p in human gastric cancer. We reveal
that miR-199a-5p level is increased in gastric cancer tis-
sues and gastric cancer lines, and miR-199a-5p overex-
pression promotes cell migration and invasion of gastric
cancer cells in vitro. Furthermore, our study shows that
klotho may be the downstream target of miR-199a-5p.
These results suggest that miR-199a-5p may play an
oncogenic role in gastric cancer by targeting klotho and
might serve as a potential therapy target of patients with
gastric cancer in future.
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